Medicare beneficiaries who start filling GLP-1 prescriptions through the new $50-per-month Bridge demonstration on July 1, 2026, will not see those payments chip away at their annual Part D out-of-pocket spending threshold. The Centers for Medicare & Medicaid Services has structured the 18-month program so that neither the $50 copay nor the $245 net price paid by plans counts toward the formula that determines when catastrophic coverage kicks in. That accounting decision, described in technical guidance for plan sponsors, sets up a quiet but significant gap for enrollees who depend on drugs like semaglutide or tirzepatide through the end of 2027 and then face standard Part D cost-sharing rules with no credit for what they already spent.
How the $50 Copay Falls Outside Part D Math
CMS built the Bridge demonstration on the Secretary’s authority under Section 402(a)(1)(A) of the Social Security Amendments of 1967, a provision that allows time-limited tests of new payment and service delivery approaches. Because the program operates outside the standard Part D benefit structure, its costs do not feed into the metric known in regulation as gross covered drug costs, or GCPDC, defined at 42 CFR 423.308. That metric is the running total that determines when a beneficiary crosses the initial coverage limit and, eventually, the catastrophic threshold where Medicare shoulders most of the tab.
In plain terms, every $50 monthly payment a beneficiary makes under the Bridge is invisible to the Part D ledger. Someone paying $50 a month for 18 months would spend $900 on GLP-1 drugs without moving a single dollar closer to the out-of-pocket cap that Congress set at $2,000 for 2025 and indexed going forward. The $245 net price that plans pay per beneficiary per month is similarly excluded, meaning the demonstration creates no progress toward catastrophic coverage for anyone involved. For beneficiaries who rely on these medicines to manage obesity or type 2 diabetes, the program effectively creates a parallel benefit track that never intersects with the standard Part D accumulation rules.
A Cost Cliff Waiting at the End of 2027
The Bridge demonstration runs from July 1, 2026, through December 31, 2027. When it expires, beneficiaries who have stabilized on GLP-1 medications for obesity or diabetes management will need to fill those same prescriptions under regular Part D rules, where list prices for popular GLP-1 drugs can exceed $1,000 a month before rebates. Their GCPDC counter will read zero for any Bridge-period spending, so they will start the 2028 benefit year with no accumulated credit toward catastrophic protection. Even if they have been continuously adherent for a year and a half, the Part D system will treat them as if they are starting GLP-1 therapy for the first time.
CMS has positioned the Bridge alongside its longer-term BALANCE model, which focuses on lifestyle and nutrition interventions for Medicare beneficiaries with obesity-related conditions. The Bridge is explicitly labeled a short-term demonstration, not a permanent benefit expansion. That framing suggests the agency views it as a stopgap while broader coverage policy takes shape, but it also means there is no built-in glide path for enrollees who will owe full Part D cost-sharing once the demonstration closes. Unless Congress or CMS changes the rules before 2028, beneficiaries who transition off the Bridge could experience a sudden jump from $50 a month to standard Part D coinsurance tied to high list prices.
What Beneficiaries Should Track Before January 2028
Several questions remain open. CMS has not detailed whether plans will be encouraged to design supplemental benefits or transition policies for members who complete the demonstration period. It is also unclear how many beneficiaries will be able to stay on GLP-1 therapy once they face standard cost-sharing, particularly those on fixed incomes who are not eligible for the Part D low-income subsidy.
Beneficiaries who enroll in the Bridge will need to keep close track of a few key issues. First, they should confirm with their plan whether their GLP-1 prescription will be on the Part D formulary in 2028 and what tier and coinsurance will apply. A drug covered through the demonstration in 2027 will not automatically have the same status once it shifts into the regular benefit. Second, they should understand that none of their demonstration-period payments will count toward the Part D out-of-pocket cap, and budget accordingly for a potential spike in early 2028 spending before they approach catastrophic protection.
Advocates are likely to press CMS to clarify how many beneficiaries it expects to enroll, how plans will be compensated, and whether lessons from the demonstration will feed into permanent coverage decisions. In a recent announcement describing the agency’s plan to provide $50 monthly access to GLP-1 medications, CMS emphasized affordability and access but did not address how the temporary structure interacts with long-term Part D protections. That omission underscores the central tension of the Bridge: it offers near-term relief for beneficiaries who could not otherwise afford GLP-1 drugs, while quietly setting up a cost cliff when the program ends.
As plans finalize their 2027 and 2028 benefit designs, the details of how GLP-1 coverage transitions from the demonstration back into the standard Part D framework will determine whether the Bridge functions as a true bridge to sustainable access or a short-lived discount followed by financial whiplash. Beneficiaries, clinicians, and policymakers will need to watch closely to ensure that the temporary fix does not leave patients worse off once the clock runs out.
